Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia
Table 3
Predictors of the percentage change in adiponectin in response to ER niacin/laropiprant.
Variables
% change in adiponectin
Univariate analysis
Multivariate analysis
Age, years
0.197
0.03
0.088
0.353
Gender (1 = male, 2 = female)
0.228
0.012
0.215
0.006
Baseline body weight, kg
−0.387
<0.001
0.068
0.475
Baseline body fat, %
−0.135
0.139
Baseline body fat mass, kg
−0.351
<0.001
−0.265
0.001
Baseline BMI, kg/m2
−0.389
<0.001
−0.003
0.972
Baseline waist circumference, cm
−0.421
<0.001
−0.04
0.672
Hypertension (1 = Yes, 2 = No)
0.273
0.002
0.207
0.008
Diabetes (1 = Yes, 2 = No)
−0.007
0.938
Baseline adiponectin levels, µg/mL
0.043
0.637
Baseline glucose levels, mmol/L
−0.063
0.493
Baseline insulin levels, mU/L
−0.272
0.003
−0.073
0.44
Baseline HOMA-IR
−0.276
0.002
0.061
0.516
% change in body weight
−0.078
0.396
% change in body fat mass
−0.235
0.01
−0.238
0.003
% change in lean body mass
0.14
0.126
% change in fasting glucose
0.221
0.015
0.189
0.015
% change in HbA1c
0.045
0.624
% change in insulin
0.184
0.043
% change in HOMA-IR
0.237
0.009
0.037
0.697
% change in FFA
0.083
0.364
% change in HDL-C
0.121
0.186
% change in triglycerides
−0.303
<0.001
−0.176
0.027
% change in LDL-C
−0.256
0.005
−0.105
0.268
Not included due to collinearity with % change in HOMA-IR. BMI: body mass index; FFA: free fatty acids; HbA1C: glycated haemoglobin; HDL-C: high-density lipoprotein cholesterol; HOMA-IR: Homeostasis Model of Assessment-Insulin Resistance; LDL-C: low-density lipoprotein cholesterol.
